| | |
C.H. Unnikrishnan and Radhieka Pandeya 10:45 PM | July 29,2009
The country’s largest drug maker by market capitalization also incurred one-time severance costs from layoffs
|
|
C.H. Unnikrishnan and Radhieka Pandeya 12:34 AM | June 27,2009
Sun, India’s largest drug maker by market value, has a 76% stake in Caraco
|
|
C.H. Unnikrishnan and Radhieka Pandeya 12:34 AM | April 20,2009
Average growth in sales for the quarter likely to be less than 11%, compared with 14% in the year-ago period
|
|
C.H. Unnikrishnan and Radhieka Pandeya 01:11 AM | February 24,2009
Glenn Saldanha, CEO Glenmark Pharmaceuticals, says all that the company needs is a couple of R&D deals to bring back investor confidence
|
|
C.H. Unnikrishnan and Radhieka Pandeya 01:04 AM | January 19,2009
Growth to weaken due to rise in costs, low margins from global markets and deals, and mark-to-market losses
|
|
C.H. Unnikrishnan and Radhieka Pandeya 11:00 PM | January 12,2009
Legal experts, health care activists question decision against Hetero; claim move violates Drugs and Cosmetics Act
|
|
C.H. Unnikrishnan and Radhieka Pandeya 11:14 PM | January 07,2009
Delhi high court stayed Hetero Drugs Ltd, which had sought approval for marketing dasatinib, from making, selling ,distributing or exporting the medicine
|
|
C.H. Unnikrishnan and Radhieka Pandeya 12:57 AM | January 07,2009
The firm claims Sun has breached an agreement to keep all settlement discussions and proposals confidential
|
|
C.H. Unnikrishnan and Radhieka Pandeya 10:29 PM | October 24,2008
Glenmark shares fall 20%; suspension may put a question mark on licensing deal with Eli Lilly for pain molecule
|
|